Participants were classified as having any SUD if they met criteria for one or more of these individual conditions
Medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) achieve weight loss of approximately 14.9 to 20% of body weight
Most people tolerate this dose without significant issues
People living with these autoimmune diseases are at a higher risk of heart problems due to the chronic inflammation associated with these diseases
Nearly all of the proceedings, 96%, were IPRs
However, stopping these therapies often leads to significant weight regain, frustrating patients and clinicians alike.[1][2] Understanding GLP-1 Agonists GLP-1 drugs mimic the gut hormone glucagon-like peptide-1, which regulates blood sugar and appetite